Cargando…
Efficacy and Safety of Treatment With Ferric Carboxymaltose in Patients With Cirrhosis and Gastrointestinal Bleeding
Background: Patients with liver cirrhosis and gastrointestinal bleeding (GIB) often develop anemia. Ferric carboxymaltose (FCM) is an intravenous (i.v.) iron formulation approved for use in patients with iron deficiency with inadequate response to oral iron therapy or when oral iron cannot be used....
Autores principales: | Ballester-Clau, Raquel, Torres Vicente, Gisela, Cucala Ramos, Mercedes, Aracil Blanch, Carles, Miñana Calafat, Josep Maria, Pijoan Comas, Eva, Reñé Espinet, Josep Maria, Planella de Rubinat, Montse |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181670/ https://www.ncbi.nlm.nih.gov/pubmed/32363194 http://dx.doi.org/10.3389/fmed.2020.00128 |
Ejemplares similares
-
Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2019) -
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
por: Calleja, José Luis, et al.
Publicado: (2015) -
Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014) -
Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020) -
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study
por: Ponikowski, Piotr, et al.
Publicado: (2015)